Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 9, Issue 10, Pages 1013-1018Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.8b00283
Keywords
Protein arginine deiminase; mechanism-based inhibitor; rheumatoid arthritis; inflammatory disease; citrullination
Categories
Funding
- NIH [R35GM122473, R01CA170741]
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM122473] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Protein arginine deiminase 4 (PAD4) is a calcium-dependent enzyme that catalyzes the conversion of arginine to citrulline within target proteins. Dysregulation of PAD4 has been implicated in a number of human diseases, including rheumatoid arthritis and other inflammatory diseases as well as cancer. In this study, we report on the design, synthesis, and evaluation of a new class of haloacetamidine-based compounds as potential PAD4 inhibitors. Specifically, we describe the identification of 4,5,6-trichloroindazole 24 as a highly potent PAD4 inhibitor that displays >10-fold selectivity for PAD4 over PAD3 and >50-fold over PAD1 and PAD2. The efficacy of this compound in cells was determined by measuring the inhibition of PAD4-mediated H4 citrullination in HL-60 granulocytes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available